Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer

Ashish M. Kamat, J. Alfred Witjes, Maurizio Brausi, Mark Soloway, Donald Lamm, Raj Persad, Roger Buckley, Andreas Böhle, Marc Colombel, Joan Palou

Research output: Contribution to journalReview article

47 Scopus citations

Abstract

Purpose Low, intermediate and high risk categories have been defined to help guide the treatment of patients with nonmuscle invasive bladder cancer (Ta, T1, CIS). However, while low and high risk disease has been well classified, the intermediate risk category has traditionally comprised a heterogeneous group that does not fit into either of these categories. As a result, many urologists remain uncertain about the categorization of patients as intermediate risk as well as the selection of the most appropriate therapeutic option for this patient population. We review the current literature and clinical practice guidelines on intermediate risk nonmuscle invasive bladder cancer and, based on our findings, provide urologists with a better understanding of this heterogeneous risk group as well as practical recommendations for the treatment of intermediate risk patients. Materials and Methods The IBCG analyzed published clinical trials, meta-analyses and current clinical practice guidelines on intermediate risk nonmuscle invasive bladder cancer available as of September 2013. The definitions of intermediate risk, patient outcomes and guideline recommendations were considered, as were the limitations of the available literature and additional parameters that may be useful in guiding treatment decisions in intermediate risk patients. Results Current definitions and management recommendations for intermediate risk nonmuscle invasive bladder cancer vary. The most simple and practical definition is that proposed by the IBCG and the AUA of multiple and/or recurrent low grade Ta tumors. The IBCG suggests that several factors should be considered in clinical decisions in intermediate risk disease, including number (greater than 1) and size (greater than 3 cm) of tumors, timing (recurrence within 1 year) and frequency (more than 1 per year) of recurrence, and previous treatment. In patients without these risk factors a single, immediate instillation of chemotherapy is advised. In those with 1 to 2 risk factors adjuvant intravesical therapy (intravesical chemotherapy or maintenance bacillus Calmette-Guérin) is recommended, and previous intravesical therapy should be considered when choosing between these adjuvant therapies. For those patients with 3 to 4 risk factors, maintenance bacillus Calmette-Guérin is recommended. It is also important that all intermediate risk patients are accurately risk stratified at initial diagnosis and during subsequent followup. This requires appropriate transurethral resection of the bladder tumor, vigilance to rule out carcinoma in situ or other potential high risk tumors, and review of histological material directly with the pathologist. Conclusions Intermediate risk disease is a heterogeneous category, and there is a paucity of independent studies comparing therapies and outcomes in subgroups of intermediate risk patients. The IBCG has proposed a management algorithm that considers tumor characteristics, timing and frequency of recurrence, and previous treatment. Subgroup analyses of intermediate risk subjects in pivotal EORTC trials and meta-analyses will be important to validate the proposed algorithm and support clear evidence-based recommendations for subgroups of intermediate risk patients.

Original languageEnglish (US)
Pages (from-to)305-315
Number of pages11
JournalJournal of Urology
Volume192
Issue number2
DOIs
StatePublished - Aug 2014

    Fingerprint

Keywords

  • adjuvant
  • administration
  • chemotherapy
  • intravesical
  • mycobacterium bovis
  • risk
  • urinary bladder neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Kamat, A. M., Witjes, J. A., Brausi, M., Soloway, M., Lamm, D., Persad, R., Buckley, R., Böhle, A., Colombel, M., & Palou, J. (2014). Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. Journal of Urology, 192(2), 305-315. https://doi.org/10.1016/j.juro.2014.02.2573